Találati lista | Tudóstér

001-es BibID:	BIBFORM089479
Első szerző:	Balogh Boglárka (belgyógyász)
Cím:	Gut barrier failure : a piece in the puzzle of acute-on chronic liver failure syndrome development? / Boglarka Balogh, Zsuzsa Vitalis, Tamas Tornai, Istvan Tornai, David Tornai, Aniko Csillag, Peter Antal-Szalmas, Maria Papp
Dátum:	2020
Megjegyzések:	Introduction: Intestinal barrier dysfunction induced inflammation facilitates pathologic bacterial translocation (BT) which is a characteristic feature of liver cirrhosis (LC). BT plays a crucial role in the progression of LC leading to spontaneous bacterial peritonitis (SBP), bacteraemia and induction of proinflammatory responses causing various organ damages. Therefore, the serological hallmarksof gut barrier dysfunction in cirrhosis are able to predict the accelerated progression of liver disease. Methods: In a cohort of patients with decompensated cirrhosis (n=135) prospectively followed-up for 1 year and in healthy controls (HC) (n=50) the serological markers of functional/structural gut damage (intestinal-fatty acid binding protein, I-FABP), BT (Endotoxin core antibody, EndoCab IgA) and mucosal immune response (secretory IgA, Immunoglobulin free light chain (Ig FLC) kappa and lambda,) were investigated by means of ELISA. Results: Comparing the LC to HC group the serum concentration of all investigated markers weresignificantly higher in cirrhotic patients, although they did not show any association with the disease severity. Investigating the role of the serological markers in the development of ACLF we found that significance of the serum level of Ig FLC kappa in ACLF prediction is comparable to AD score based on AUC values. Furthermore, the ACLF rate was lower in patients with low serum concentration of Ig FLC kappa compared to the group with high serum concentration of this molecule. Conclusions: Ig FLC kappa can be a usable marker in the serological panel for the prediction of ACLF development in acute decompensated cirrhotic patients. Acknowledgements: EFOP 3.6.2-16-2017-00006 (LIVE LONGER).
Tárgyszavak:	Orvostudományok Klinikai orvostudományok előadáskivonat könyvrészlet
Megjelenés:	Proceedings of the EFOP-3.6.2-16-2017-00006 (LIVE LONGER) project /Ed. Rakonczay Zoltán, Kiss Lóránd. - p. 62. -
További szerzők:	Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Tornai István (1954-) (belgyógyász, gasztroenterológus) Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Csillag Anikó (1979-) (immunológus, biológus, angol-magyar szakfordító) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:	EFOP-3.6.2-16-2017-00006 EFOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM089481
Első szerző:	Csillag Anikó (immunológus, biológus, angol-magyar szakfordító)
Cím:	Filamentosus-actin related molecules : are they serologic hallmark of overwhelming damage-associated molecular patterns (DAMPs) in acute decompensation? / Aniko Csillag, Zsuzsa Vitalis, Tamas Tornai, Istvan Tornai, David Tornai, Boglarka Balogh, Peter Antal-Szalmas, Maria Papp
Dátum:	2020
Megjegyzések:	Introduction: The actin cytoskeleton has a fundamental function in cellular motility, integrity, structure and signaling mechanisms. In acute decompensated liver cirrhosis large quantities of filamentous actin (F-actin) as a danger signal is released from damaged and necrotic hepatic cells. Recently it also has been demonstrated that the presence of IgA type anti-F-actin antibodies is associated with the disease severity, unfavorable disease outcome and intestinal damage, as well. Thus, we hypothesized that the actin-scavenging system molecules in acute decompensation are able to predict the accelerated progression of liver disease. Methods: In a cohort of patients with decompensated cirrhosis (n=135) prospectively followed-up for 1 year and in healthy controls (HC, n=50) the serum levels of gelsolin and anti-F-actin IgA were investigated by means of ELISA. Results: Serum gelsolin levels were significantly higher in patients with acute decompensated liver cirrhosis (LC-AD) compared to healthy controls (HCONT) (p<0.0001). The frequency of anti-F-actin positivity was 65.4% (n=83/127) in LC-AD group (cut off: 25 U/mL). Our results demonstrated that in LC-AD group the serum gelsolin levels did not show correlation with the different disease severity, the presence of bacterial infection or renal failure at inclusion, similarly to the presence or absence of anti-F-actin IgA positivity. However, high serum level of gelsolin (>87.7 ?g/mL) is associated with short term (30 days) mortality. Conclusions: High serum level of gelsolin is likely to predict short term mortality both in cirrhotic patients with or without acute-on-chronic liver failure at inclusion. Acknowledgements: EFOP 3.6.2-16-2017-00006 (LIVE LONGER).
ISBN:	978-963-306-764-2
Tárgyszavak:	Orvostudományok Klinikai orvostudományok előadáskivonat könyvrészlet
Megjelenés:	"PROCEEDINGS OF THE EFOP-3.6.2- 16-2017-00006 (LIVE LONGER) PROJECT" / Ed. Rakonczay Zoltán, Kiss Lóránd. - p. 63. -
További szerzők:	Vitális Zsuzsanna (1963-) (belgyógyász, gasztroenterológus) Tornai Tamás István (1984-) (belgyógyász) Tornai István (1954-) (belgyógyász, gasztroenterológus) Tornai Dávid (1989-) (hepatológia, biomarker kutatás) Balogh Boglárka (1993-) (belgyógyász) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:	EFOP-3.6.2-16-2017-00006 EFOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: